HelioLiver LDT now available to order through Quest Diagnostics
Abstract science and finance imagery
News & Media

Lab Raises $86 Million for a ‘Breakthrough’ Liver Cancer Test

Media Coverage Nov 15, 2019 5 min read Cheddar
Share

Laboratory for Advanced Medicine (now Helio Genomics) raised $86 million to develop its liver cancer blood test; CEO Kenneth Chahine discussed it on Cheddar.

Featured on Cheddar.

The Laboratory for Advanced Medicine — the company that would become Helio Genomics — raised $86 million to further develop its blood test that can detect liver cancer. CEO Kenneth Chahine joined Cheddar to discuss the raise and the company’s methylation-based approach to early cancer detection.

Watch the interview on Cheddar →

Read the Full Article

Source: Cheddar. Read the full article.

Related Articles

More from Helio Genomics

NewsMay 12, 2026

HelioLiver Expands Access Through Quest

Helio broadens access to HelioLiver through Quest Diagnostics’ nationwide network of patient service centers.

Read more
NewsMay 8, 2026

Collaborating with the Rural Health Transformation Collaborative, Co-Chaired by Microsoft

Helio joins the Rural Health Transformation Collaborative, co-chaired by Microsoft, to expand rural early detection.

Read more
VoicesMay 6, 2026

Bharat Tewarie: Giving Patients a “Real Fighting Chance” Against Liver Cancer

Helio’s CEO reflects on the landmark CLiMB study and what earlier liver cancer detection means for patients.

Read more